|Other Names||Signal transducer and activator of transcription 5B, STAT5B|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1530a was selected from the C-term region of human STAT5b. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription.|
|Cellular Location||Cytoplasm. Nucleus. Note=Translocated into the nucleus in response to phosphorylation.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
STAT5b is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein mediates the signal transduction triggered by various cell ligands, such as IL2, IL4, CSF1, and different growth hormones. It has been shown to be involved in diverse biological processes, such as TCR signaling, apoptosis, adult mammary gland development, and sexual dimorphism of liver gene expression. This gene was found to fuse to retinoic acid receptor-alpha (RARA) gene in a small subset of acute promyelocytic leukemias (APLL). The dysregulation of the signaling pathways mediated by this protein may be the cause of the APLL.
Xi, S., et al., Cancer Res. 63(20):6763-6771 (2003).Uddin, S., et al., Biochem. Biophys. Res. Commun. 308(2):325-330 (2003).Zhang, X., et al., J. Allergy Clin. Immunol. 112(1):93-101 (2003).Yamashita, H., et al., Oncogene 22(11):1638-1652 (2003).Kloth, M.T., et al., J. Biol. Chem. 278(3):1671-1679 (2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.